StockData
GRI Bio, Inc. logo

GRI Bio, Inc. (GRI) stock

GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.35−0.05 (-3.54%)

Close on Nov 17, 2026Market cap $2.95MP/E –Yield –

GRI Bio cash

Cash and short-term investments held at the end of each period.

GRI Bio's cash was $10.95M at Jun 30, 2026. For fiscal 2025 it was $8.23M, up 63.7% from the year before. The highest annual figure on record is $8.23M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.23M+63.7%
FY2024Dec 31, 2024$5.03M+178.1%
FY2023Dec 31, 2023$1.81M+19988.9%
FY2022Dec 31, 2022$9.00K-99.9%
FY2021Dec 31, 2021$7.51M+6789.9%
FY2020Dec 31, 2020$109.00K-97.1%
FY2019Dec 31, 2019$3.82M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.95M+113.7%
Q1 FY2026Mar 31, 2026$11.05M+236.7%
Q4 FY2025Dec 31, 2025$8.23M+63.7%
Q3 FY2025Sep 30, 2025$4.06M-14.6%
Q2 FY2025Jun 30, 2025$5.12M-19.4%
Q1 FY2025Mar 31, 2025$3.28M-19.8%
Q4 FY2024Dec 31, 2024$5.03M+178.1%
Q3 FY2024Sep 30, 2024$4.75M+36.1%
Q2 FY2024Jun 30, 2024$6.35M+32.4%
Q1 FY2024Mar 31, 2024$4.09M+145.7%
Q4 FY2023Dec 31, 2023$1.81M+19988.9%
Q3 FY2023Sep 30, 2023$3.49M-32.3%
Q2 FY2023Jun 30, 2023$4.80M-31.1%
Q1 FY2023Mar 31, 2023$1.67M-67.8%
Q4 FY2022Dec 31, 2022$9.00K-99.9%
Q3 FY2022Sep 30, 2022$5.15M-43.6%
Q2 FY2022Jun 30, 2022$6.97M-33.4%
Q1 FY2022Mar 31, 2022$5.18M-60.1%
Q4 FY2021Dec 31, 2021$7.51M+6789.9%
Q3 FY2021Sep 30, 2021$9.14M+889.0%
Q2 FY2021Jun 30, 2021$10.46M+423.3%
Q1 FY2021Mar 31, 2021$12.98M+329.2%
Q4 FY2020Dec 31, 2020$109.00K-97.1%
Q3 FY2020Sep 30, 2020$924.00K–
Q2 FY2020Jun 30, 2020$2.00M–
Q1 FY2020Mar 31, 2020$3.02M–
Q4 FY2019Dec 31, 2019$3.82M–

More GRI Bio figures

See a number that looks wrong?